E1A通过E6/E6AP增强宫颈癌放疗敏感性的分子机理研究
结题报告
批准号:
81372792
项目类别:
面上项目
资助金额:
70.0 万元
负责人:
申良方
依托单位:
学科分类:
H1816.肿瘤放射治疗
结题年份:
2017
批准年份:
2013
项目状态:
已结题
项目参与者:
汤参娥、刘游鸿、申海菊、贺玉香、雷明军、周琴、黄昕琼、李玲玉、田一夫
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
宫颈癌放疗抵抗是亟待解决的重要临床问题,探索有效的放疗增敏手段具有重要的临床意义。我们的前期工作表明:利用E1A进行宫颈癌的基因治疗可有效增强细胞的放疗敏感性,观察到的增敏效应与p53表达升高导致的宫颈癌细胞凋亡有关,但E1A放疗增敏的分子机制仍有待深入探讨。99%的宫颈癌患者为HPV阳性,高危型HPV编码的E6蛋白与E6相关蛋白(E6AP)形成复合物降解p53是HPV阳性细胞内p53低水平表达的主要原因。本项目拟通过体内外实验阐明E1A通过干扰E6-E6AP复合物的形成,影响p53降解途径,实现其放疗增敏作用;并通过免疫共沉淀和激光共聚焦显微技术,证明E1A与E6AP的结合;利用表达不同E6AP和E1A基因区域的质粒在细胞中确定E1A与E6AP的相互结合区域;采取体外泛素化降解分析技术,阐明E1A通过E6AP抑制P53降解过程的分子机制,从而为宫颈癌的新的放疗/生物治疗手段提供实验基础。
英文摘要
Radiation resistance of cervical cancer has become an important clinical problem in current treatment which to be resolved. It is one of the urgent problxems to explore a good adjunctive treatment which has better effect of increasing radiosensitivity. Our preliminary tests suggest that gene therapy which mediated by E1A can enhance the cancer's radiosensitivity effectively and the improvement of the radiosensitivity has relevance to apoptosis of cervical cancer cells result from the upregulation of p53 expression.However, the molecular mechanism for E1A increasing the radiosensitivity should be investigated. 99% of the patients with cervical cancer are positive for HPV infection. The E6 protein which encoded by high-risk HPV form a compound with E6 associated protein(E6AP) induce p53 degradation, which is the main reason why p53 is expressed lowly in HPV positive cells. In our study, we try to demonstrate that E1A affects the degradation of p53 through interfering the process of E6 and E6AP forming complexes in vitro and in vivo so that E1A can increase the radiosensitivity. Then, we want to illustrate that E1A and E6AP can be combined with each other by immunoprecipitate and the laser scanning confocal microscope. Furthermore, we will identify the combined domain of E1A and E6AP in cancer cells assisted by the plasmids which express different gene functional domain of E1A and E6AP. In the end, we plan to adopt the in vitro ubiquitination degradation analysis to demonstrate the procedure in which the E1A repress the p53 degradation through the E6AP pathway. Our study will demonstrate the molecular mechaniam of E1A increasing the radiosensitivity and offer an experimental fundament for new radio-biotherapy treatments of cevical carcinoma.
宫颈癌放疗抵抗是亟待解决的重要临床问题,探索有效的放疗增敏手段具有重要的临床意义。99%的宫颈癌患者为HPV阳性,高危型HPV编码的E6蛋白与E6相关蛋白(E6AP)形成复合物降解p53是HPV阳性细胞内p53低水平表达的主要原因。我们的研究工作表明:利用E1A进行宫颈癌的基因治疗可有效增强HPV阳性宫颈癌细胞系的放疗敏感性,观察到的增敏效应与p53表达升高导致的宫颈癌细胞凋亡有关,E1A通过干扰E6-E6AP复合物的形成,与E6AP相互结合使得p53泛素化降解减少,实现其放疗增敏作用,具体的结合结构域可能在CR1这个保守区域。本研究为宫颈癌新的放疗/生物治疗手段提供实验基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma
骨桥蛋白和E-钙粘蛋白的异常表达表明宫颈癌患者的放射抵抗和不良预后
DOI:10.1369/0022155414561329
发表时间:2015-02-01
期刊:JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
影响因子:3.2
作者:Huang, Xinqiong;Qian, Yujie;Chen, Xiang
通讯作者:Chen, Xiang
DOI:--
发表时间:2014
期刊:INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
影响因子:1.4
作者:Huang Xin-Qiong;Chen Xiang;Xie Xiao-Xue;Zhou Qin;Li Kai;Li Shan;Shen Liang-Fang;Su Juan
通讯作者:Su Juan
DOI:--
发表时间:2015
期刊:INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
影响因子:1.4
作者:Huang Xinqiong;Liu Miaomiao;Sun Hong;Wang Fengjun;Xie Xiaoxue;Chen Xiang;Su Juan;He Yuxiang;Dai Youyi;Wu Haijun;Shen Liangfang
通讯作者:Shen Liangfang
DOI:10.1369/0022155414532654
发表时间:2014-07-01
期刊:JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
影响因子:3.2
作者:Shen, Liangfang;Huang, Xinqiong;Chen, Xiang
通讯作者:Chen, Xiang
DOI:10.14670/hh-11-627
发表时间:2015-11-01
期刊:HISTOLOGY AND HISTOPATHOLOGY
影响因子:2
作者:Zhao,Yajie;Shen,Liangfang;Huang,Xinqiong
通讯作者:Huang,Xinqiong
MDK诱导的自噬通过代谢重编程维持肿瘤干细胞干性参与胶质瘤复发和放疗抵抗
  • 批准号:
    81974466
  • 项目类别:
    面上项目
  • 资助金额:
    51.0万元
  • 批准年份:
    2019
  • 负责人:
    申良方
  • 依托单位:
国内基金
海外基金